Martín, ErnestoLópez-Aguilera, JoséGonzález-Manzanares, RafaelAnguita, ManuelGutiérrez, GuillermoLuque, AuroraParedes, NickOneto, JesúsPerea, JorgeCastillo, Juan Carlos2025-01-072025-01-072021-02-012077-0383https://hdl.handle.net/10668/28309Heart failure (HF) is one of the mayor contributors to cardiovascular morbidity and mortality in patients with diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated to reduce the risk of hospitalization for HF in patients with type 2 diabetes mellitus (T2D). We aimed to assess the risk for re-hospitalization in a cohort of patients hospitalized for HF according to whether or not they received canagliflozin at discharge, as well as changes in N-terminal pro-B-type natriuretic peptide (NT-ProBNP) concentration during follow-up. We conducted a retrospective longitudinal study at a tertiary centre including 102 consecutive T2D patients discharged for acute HF without contraindication for SGLT2 inhibitors. We compared adverse clinical events (HF rehospitalization and cardiovascular death) and NT-ProBNP changes according to canagliflozin prescription at discharge. Among the 102 patients included, 45 patients (44.1%) were prescribed canagliflozin and the remaining 57 (55.9%) were not prescribed any SGLT2 inhibitors (control group). After a median follow-up of 22 months, 45 patients (44.1%) were hospitalized for HF. Most of the rehospitalizations occurred during the first year (37.3%). HF readmission at first year occurred in 10 patients (22.2%) in the canagliflozin group and 29 patients (49.1%) in the control group (hazard ratio (HR): 0.45; 95% confidence interval (CI): 0.21-0.96; p Canagliflozin therapy at discharge was associated with a lower risk of readmission for HF and a reduction in NT-ProBNP concentration in patients with diabetes after hospitalization for HF.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/N-terminal pro-B-type natriuretic peptidecanagliflozinheart failurereadmissionssodium glucose co-transporter 2 inhibitorresearch article33535424open access10.3390/jcm10030505PMC7867051https://www.mdpi.com/2077-0383/10/3/505/pdf?version=1612164469https://pmc.ncbi.nlm.nih.gov/articles/PMC7867051/pdf